Cargando…

Hallmarks of response to immune checkpoint blockade

Unprecedented advances have been made in the treatment of cancer through the use of immune checkpoint blockade, with approval of several checkpoint blockade regimens spanning multiple cancer types. However, responses to this form of therapy are not universal, and insights are clearly needed to ident...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cogdill, Alexandria P, Andrews, Miles C, Wargo, Jennifer A
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Minireview
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520201/ https://www.ncbi.nlm.nih.gov/pubmed/28524159 http://dx.doi.org/10.1038/bjc.2017.136

Ejemplares similares

Radiotherapy as an immune checkpoint blockade combination strategy for hepatocellular carcinoma
por: Lee, Byung Min, et al.
Publicado: (2021)

Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
por: Wei, Spencer C., et al.
Publicado: (2019)

Hallmarks of Resistance to Immune-Checkpoint Inhibitors
por: Karasarides, Maria, et al.
Publicado: (2022)

Angiogenesis and immune checkpoint dual blockade: Opportunities and challenges for hepatocellular carcinoma therapy
por: Li, Si-Qi, et al.
Publicado: (2022)

Hallmarks of cancer stem cell metabolism
por: Sancho, Patricia, et al.
Publicado: (2016)

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers
por: Hopkins, Ashley M, et al.
Publicado: (2017)

Microbiome influencers of checkpoint blockade–associated toxicity
por: Wang, Yinghong, et al.
Publicado: (2023)

Immune checkpoint inhibitor-induced colitis: A comprehensive review
por: Som, Aniruddh, et al.
Publicado: (2019)

Evidence of synergy with combined BRAF-targeted therapy and immune checkpoint blockade for metastatic melanoma
por: Cooper, Zachary A, et al.
Publicado: (2014)

Immune checkpoint inhibitor-related hepatotoxicity: A review
por: Remash, Devika, et al.
Publicado: (2021)

Immune checkpoint inhibitor-induced diarrhea/colitis: Endoscopic and pathologic findings
por: Nishida, Tsutomu, et al.
Publicado: (2019)

G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer
por: Bucher, N, et al.
Publicado: (2008)

The decatenation checkpoint
por: Damelin, M, et al.
Publicado: (2007)

Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer
por: Kang, Yong-Bo, et al.
Publicado: (2021)

Differential diagnosis and management of immune checkpoint inhibitor-induced colitis: A comprehensive review
por: Li, Hua, et al.
Publicado: (2021)

Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
por: Amaria, Rodabe N., et al.
Publicado: (2018)

Predictors of responses to immune checkpoint blockade in advanced melanoma
por: Jacquelot, N., et al.
Publicado: (2017)

Hyperprogression under treatment with immune-checkpoint inhibitors in patients with gastrointestinal cancer: A natural process of advanced tumor progression?
por: Wang, Mo-Xuan, et al.
Publicado: (2022)

The Puzzle of Predicting Response to Immune Checkpoint Blockade
por: Onyshchenko, Mykola
Publicado: (2018)

Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer Therapy
por: Andrews, Miles C., et al.
Publicado: (2018)

Checkpoint inhibitors: What gastroenterologists need to know
por: Ahmed, Monjur
Publicado: (2018)

Activation of phagocytosis by immune checkpoint blockade
por: Li, Chia-Wei, et al.
Publicado: (2018)

Emerging Therapies for Diabetic Nephropathy Patients: Beyond Blockade of the Renin-Angiotensin System
por: Tanios, Bassem Y., et al.
Publicado: (2012)

Microbial mechanisms to improve immune checkpoint blockade responsiveness
por: Griffin, Matthew E., et al.
Publicado: (2022)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Use of programmed cell death protein ligand 1 assay to predict the outcomes of non-small cell lung cancer patients treated with immune checkpoint inhibitors
por: Tibaldi, Carmelo, et al.
Publicado: (2017)

Multiparametric analysis of colorectal cancer immune responses
por: Leman, Julia KH, et al.
Publicado: (2018)

Epigenetics modulates the complexity of the response to Immune Checkpoint Blockade
por: Barragan, Isabel
Publicado: (2020)

The Tumor Microenvironment in the Response to Immune Checkpoint Blockade Therapies
por: Petitprez, Florent, et al.
Publicado: (2020)

Genetic and Epigenetic Biomarkers of Immune Checkpoint Blockade Response
por: Xiao, Qingyang, et al.
Publicado: (2020)

An immunomodulatory signature of responsiveness to immune checkpoint blockade therapy
por: Shen, Hongru, et al.
Publicado: (2020)

Metabolic predictors of response to immune checkpoint blockade therapy
por: Shorer, Ofir, et al.
Publicado: (2023)

Radiation recall pneumonitis induced by PD-1/PD-L1 blockades: mechanisms and therapeutic implications
por: Teng, Feifei, et al.
Publicado: (2020)

Roles of Endoplasmic Reticulum Stress in Immune Responses
por: So, Jae-Seon
Publicado: (2018)

Sliding set-points of immune responses for therapy of autoimmunity
por: Hsieh, Chyi-Song, et al.
Publicado: (2010)

An Impaired Inflammatory and Innate Immune Response in COVID-19
por: Park, Sung Ho
Publicado: (2021)

Sex-specific differences in immunogenomic features of response to immune checkpoint blockade
por: Scott, Susan C., et al.
Publicado: (2022)

Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy
por: Ippolito, Davide, et al.
Publicado: (2021)

Defining unique clinical hallmarks for immune checkpoint inhibitor-based therapies
por: Michielin, Olivier, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0b8rk68ls0pelh7c0ndq10jh93